KineMed, Inc. Announces an Agreement With MedImmune to Study Protein Dynamics Related to Neurodegenerative Diseases

EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed Inc. (www.kinemed.com) today announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to study how a monoclonal antibody affects the dynamics of the cellular prion protein (PrPc).

Help employers find you! Check out all the jobs and post your resume.

Help employers find you! Check out all the jobs and post your resume.

Back to news